RMIT University
Browse

Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer

journal contribution
posted on 2024-11-02, 01:58 authored by Carmela Martini, Jessica Logan, Alexandra Sorvina, Colin Gordon, Stavros SelemidisStavros Selemidis
Diagnosis and assessment of patients with prostate cancer is dependent on accurate interpretation and grading of histopathology. However, morphology does not necessarily reflect the complex biological changes occurring in prostate cancer disease progression, and current biomarkers have demonstrated limited clinical utility in patient assessment. This study aimed to develop biomarkers that accurately define prostate cancer biology by distinguishing specific pathological features that enable reliable interpretation of pathology for accurate Gleason grading of patients. Online gene expression databases were interrogated and a pathogenic pathway for prostate cancer was identified. The protein expression of key genes in the pathway, including adaptor protein containing a pleckstrin homology (PH) domain, phosphotyrosine-binding (PTB) domain, and leucine zipper motif 1 (Appl1), Sortilin and Syndecan-1, was examined by immunohistochemistry (IHC) in a pilot study of 29 patients with prostate cancer, using monoclonal antibodies designed against unique epitopes. Appl1, Sortilin, and Syndecan-1 expression was first assessed in a tissue microarray cohort of 112 patient samples, demonstrating that the monoclonal antibodies clearly illustrate gland morphologies. To determine the impact of a novel IHC-assisted interpretation (the utility of Appl1, Sortilin, and Syndecan-1 labelling as a panel) of Gleason grading, versus standard haematoxylin and eosin (H&E) Gleason grade assignment, a radical prostatectomy sample cohort comprising 114 patients was assessed. In comparison to H&E, the utility of the biomarker panel reduced subjectivity in interpretation of prostate cancer tissue morphology and improved the reliability of pathology assessment, resulting in Gleason grade redistribution for 41% of patient samples. Importantly, for equivocal IHC-assisted labelling and H&E staining results, the cancer morphology interpretation could be more accurately applied upon re-review of the H&E tis

History

Related Materials

  1. 1.
    DOI - Is published in 10.1016/j.pathol.2022.08.001
  2. 2.
    ISSN - Is published in 00313025

Journal

Pathology

Volume

55

Issue

1

Start page

40

End page

51

Total pages

12

Publisher

Elsevier

Place published

United Kingdom

Language

English

Copyright

© 2022 The Authors. Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Former Identifier

2006118271

Esploro creation date

2023-03-01

Usage metrics

    Scholarly Works

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC